EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tectorigenin Ameliorates Glucocorticoid‐Induced Osteoporosis by Inhibiting the NF ‐ κB Signal Pathway and Modulating Treg‐Th17 Cell Balance

Peng Peng iD, Puiian Wong, Zheng Lv, Jiaqing Tian, Wei He, Qiushi Wei, Hui Mo, Mincong He

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Peng Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Guangdong Provincial Second Hospital of Traditional Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Osteoporosis, NF-kappa B, Signal Transduction, Glucocorticoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the General Project of State Key Laboratory of Traditional Chinese Medicine Syndrome, National Natural Science Foundation of China, Foundation of Guangdong Research Institute for Orthopedics and Traumatology of Chinese Medicine for Youth Scientists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucocorticoid‐induced osteoporosis is a common clinical orthopaedic disease, primarily due to excessive use of hormones. Tectorigenin has shown a certain efficacy in treating osteoporosis, but its underlying mechanisms are not yet fully understood. This study aimed to evaluate tectorigenin (TEC)'s potential in treating glucocorticoid‐induced osteoporosis (GIOP) by restoring the osteoclast–osteoblast balance. By employing molecular docking to study TEC–RANKL interaction and RNA sequencing to map TEC's anti‐osteoporotic pathways, we conducted in vitro tests on TEC's effects on osteoclast differentiation, bone resorption, ROS production, and NF‐κB activation. We performed a luciferase reporter assay for Nrf2 and NF‐κB activities and evaluated TEC's in vivo efficacy using a GIOP mouse model with micro‐CT and histomorphometric analyses, measuring serum RANKL levels and Treg/Th17 cell ratios. Docking analysis confirmed TEC's specific binding to RANKL and RNA sequencing showed TEC modulated osteoclast pathways. In vitro, TEC suppressed osteoclastogenesis, bone resorption, osteoclast gene expression, and ROS activity by downregulating NFATc1 and modulating NF‐κB. The luciferase assay revealed TEC inhibited Nrf2 and influenced its interaction with NF‐κB. In vivo, TEC protected against GIOP by balancing Th17/Treg cells to inhibit osteoclast differentiation and maintain bone volume. In conclusion, tectorigenin (TEC) shows promise in reducing osteoclastogenesis and preventing GIOP, making it a potential drug candidate for osteoporosis management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisNF-kappa BSignal TransductionGlucocorticoidsIsoflavonesTh17 CellsT-Lymphocytes, RegulatoryAnimalsMiceRANK LigandOsteoclastsNF-E2-Related Factor 2Molecular Docking SimulationOsteogenesisCell DifferentiationDisease Models, AnimalBone ResorptionMice, Inbred C57BLReactive Oxygen SpeciesFemale

Stichwörter der Autor:innen

RANKLTh17/Tregosteoclastosteoporosistectorigenin

Substanzen

NF-kappa BtectorigeninGlucocorticoidsIsoflavonesRANK LigandNF-E2-Related Factor 2Reactive Oxygen Species

Autor:innen und Institutionen

  • Department of Orthopedics, Guangdong Provincial Second Hospital of Traditional Chinese Medicine, Guangzhou, China.
  • State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou, China.
  • Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, China.
  • Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
  • The First People's Hospital of Zhaoqing, Zhaoqing, China.

ORCID-Profile: Peng Peng

Förderung

  • the General Project of State Key Laboratory of Traditional Chinese Medicine Syndrome
  • National Natural Science Foundation of China
  • Foundation of Guangdong Research Institute for Orthopedics and Traumatology of Chinese Medicine for Youth Scientists
  • Guangdong Provincial Medical Research Fund Project
  • Guangdong Provincial Second Hospital of Chinese Medicine Research Innovation Fund Project

Zitieren

APA

Peng, P., Wong, P., Lv, Z., Tian, J., He, W., Wei, Q., Mo, H., & He, M. (2025). Tectorigenin Ameliorates Glucocorticoid‐Induced Osteoporosis by Inhibiting the NF ‐ κB Signal Pathway and Modulating Treg‐Th17 Cell Balance. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70705

Vancouver

Peng P, Wong P, Lv Z, Tian J, He W, Wei Q, et al. Tectorigenin Ameliorates Glucocorticoid‐Induced Osteoporosis by Inhibiting the NF ‐ κB Signal Pathway and Modulating Treg‐Th17 Cell Balance. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70705

BibTeX
@article{Peng2025,
  author = {Peng, Peng and Wong, Puiian and Lv, Zheng and Tian, Jiaqing and He, Wei and Wei, Qiushi and Mo, Hui and He, Mincong},
  title = {Tectorigenin Ameliorates Glucocorticoid‐Induced Osteoporosis by Inhibiting the NF ‐ κB Signal Pathway and Modulating Treg‐Th17 Cell Balance},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70705}
}
Kostenlos starten →